XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaborative Arrangements - Narrative (Details)
course in Millions, $ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
Jan. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Sep. 30, 2022
USD ($)
course
Mar. 31, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
market
course
Sep. 30, 2021
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Amortization           $ 1,623 $ 1,231
Number of markets (more than) | market           40  
Remaining minimum courses committed (in courses) | course     0.8     0.8  
Sales     $ 14,959   $ 13,154 $ 45,453 35,183
Operating Segments              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Sales     14,334   12,913 44,146 35,021
Operating Segments | Pharmaceutical              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Sales     12,963   11,496 39,826 30,714
Lynparza              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Amortization       $ 250      
Lynparza | Other Noncurrent Assets              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Finite-lived intangible assets     1,500     1,500  
Lenvima | Operating Segments | Pharmaceutical              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Sales     202   188 660 498
Lenvima | Other Noncurrent Assets              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Finite-lived intangible assets     867     867  
Verquvo | Other Intangible Assets              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Finite-lived intangible assets     53     53  
Adempas | Operating Segments | Pharmaceutical              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Sales     57   59 181 188
Adempas | Other Intangible Assets              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Finite-lived intangible assets     597     597  
Alliance Revenue - Reblozyl | Operating Segments | Pharmaceutical              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Sales     39   $ 0 124 $ 0
AstraZeneca | Sales-Based Milestones | Lynparza              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Probable contingent payments       600      
Liabilities       $ 600      
Milestone payments accrued but not yet paid     600     600  
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Lynparza              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Sales-based milestone payments           400  
Potential future sales-based milestone payments     2,100     2,100  
Capitalized milestone payment           250  
Potential future regulatory milestone payments     1,200     1,200  
Eisai              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
License option payment related to collaborative arrangement   $ 125          
Eisai | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Lenvima              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Sales-based milestone payments           600  
Potential future sales-based milestone payments     $ 2,600     2,600  
Capitalized milestone payment           $ 50  
Bayer AG | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Sales-based milestone payments $ 400            
Bristol Myers Squibb | Licensing Agreements              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Royalty rate, deduction           0.50  
Royalties           $ 104  
Bristol Myers Squibb | Licensing Agreements | Sales-Based Milestones              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Contingent milestone payments collaborative arrangement           80  
Bristol Myers Squibb | Licensing Agreements | Regulatory Milestones              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Contingent milestone payments collaborative arrangement           $ 20  
Bristol Myers Squibb | Licensing Agreements | Minimum              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Royalty rate           20.00%  
Bristol Myers Squibb | Licensing Agreements | Maximum              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Royalty rate           24.00%